MAIA Biotechnology (MAIA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
19 May, 2026Related party transactions
Radu Vitoc, brother of the CEO, received $286,321 in 2025: $213,000 in cash and 39,000 options valued at $73,321.
In 2024, Radu Vitoc received $242,102: $172,500 in cash and 50,000 options valued at $69,602.
Compensation for Radu Vitoc in both years was stated to be in line with industry standards.
Voting matters and shareholder proposals
Proxies submitted before this amendment remain valid unless changed by shareholders with a later-dated proxy.
Instructions for voting or submitting proxies are detailed in the Proxy Statement.
Partial view of Summaries dataset, powered by Quartr API
Latest events from MAIA Biotechnology
- Directors elected and auditors ratified, with 61.88% shareholder participation.MAIA
AGM 202622 May 2026 - $33M equity raise boosts cash to $34.4M, funding Phase 3 NSCLC trial; net loss rises to $6.37M.MAIAQ1 202611 May 2026
- Proxy statement amended to disclose equity compensation plan details and available shares.MAIAProxy filing27 Apr 2026
- Election of directors and auditor ratification headline the 2026 virtual annual meeting.MAIAProxy filing7 Apr 2026
- Virtual meeting to elect directors and ratify auditor, with strong governance and director alignment.MAIAProxy filing7 Apr 2026
- Advanced clinical pipeline and $33M capital raise position company for pivotal 2026 milestones.MAIAQ4 202523 Mar 2026
- THIO's pivotal trials show high efficacy in cancer, with major milestones and approvals expected by 2026.MAIABiotech Showcase 2025 Investor Conference10 Jan 2026
- Key votes include director elections, auditor ratification, and a major share authorization increase.MAIAProxy Filing2 Dec 2025
- Shareholders will vote on director elections, auditor ratification, and doubling authorized shares.MAIAProxy Filing2 Dec 2025